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i\dolesccuce and contraception

Donald .E G:reydanus\ MD,
Carolyn M Lentzsch-Pa:rcells~ MDt
Hatim A Omar~ l\1.0~
and Colleen B Dodkh, MD
Department ofPed)(ltric and Adolescent Medici.11e,
Western Michigan UrJversity School of Medicine,
KaLnnazoo, lVIichigan and i\dol,:scent Medicine and
Young Parent Programs, J422 Kentucky Clinic,
Department ofPedmtrics, Kentucky Children· s Hospital,
l.Jnivcrsity of Kentucky College ofMedicine,
Lexington, Kentucky, Un.ited States of lunericn

'11Ie age of ado{escencc: is· the

bJ11e

·vvhcn mos·1 adolescf}nts

in the world beCQme sexually active with resultant millions

of pregnancies and sexucdly transmitted disease~. This
paper considers methods of contraception fbr ll-Jese
adolescents, inchJding oral contraceptives, transdt.;tmal
contraception, tJ}in.i"-pi!is, intrnvagina1 r3ng~ h1jectab1e
contraGeplion, intrauterine devices, barrier contraceptives,
implants; l:'..nd 0thers. It is impm1ant for clinicians qrhg for
sexually active ym;th t.o provide informatl011 regarding
c.ontraGeptie:n and appropriate contraceptjve prescriptions.
Key;>.·ord&:

Adoles~;t:rx:e,

contraception

In troduetion
The median age of first intercourse in the United
States, \\7estern Europe, Eastetn Europe (Ukraine),

Eurasia (Russia), and other parts of thl: world is 16
years of age, with man:;' youth having multiple sexm:J
partners. CEnicians caring for adolescents should ask
about possible coital behavior and provide effective
contra(:eption to those youth continuing to be sexually
active without in.hmt of becoming pregnant (1-23).
Table 1 lists questions helpful to ask when discussing
contraception with adolescents "particularly i.C they
are sexually active.
A number o1 effective and safe ccntraceptivc
methods (see Table 2) are ayailabk fol the sexually
active adolescent who v-:ishes to avoid pregnancy. The
most effeGtive tnethods of contraception indutk
abstinence, comb!r;ed oral contraceptives (24},
tnmsdcrrna1 contra;,:eptive patch (Ortho Evra®),
vaginal contraceptive dng (NuvaRing@)~ progesbnreleasing implant (lmplancm®), lUDs, and
' Co:rrespondence: Profess:)r Don<il<.l E Grcydanus, MD,
Uepmtmcnt of Pediatric and Ad.nlegcent Mcdicine,
Pediati"ics Program Director iltld Feunding Chir, West:;n:

Michigan

Univ,~rsity

Sdwol

~lf :11-'fedbne,

l ODO Cak!and

Drive, Kalama:-:no, MI 49008-l2R4 Cnited States. E-tnail:

donal d.g;-cydanu ~@mc:d.·wmich. ed u

intrarnuscular medroxy-pwgesterom: acetate (DepoProvcra, DMPA): these method~ have pregnancy rates

;mder l/100 woman years ofuse (see Table 3).
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Tabk l. Questifms for Adol~~cents Sec.!iing C\lntra~eptio;n
.-····-··~...

L

2.
3.
4.

S.

6.
7.
8.
9.

.....-. - . , . , - - - : - - - - - - - - . .................-.......... _........-....

··-·~·~·-·-··-·_._

~----~--------~

W1Jat :methods have you used before, if any?
Did )lOU have <my problems with your previous method? \\1lat did you like/dislike?
Do you have any concerns about the diffenmt methods of contraception?
If your friends use contraception, what comrnertts have :hey made?
\ViE you he able to use these methods correctly? Which ones?
Is your W(;;ight of concern to ym1'? Ihve you been m· are you now dieting?
Sorne methods may lead tc unplarmed, irregulat bleeding. Can you de~•l vvlH1 that?
.
:r~ve -~m;_ het.rd about any problems with the pill or ether methods, snch as possible weight gain or

i

~~~:

I

Ate you 2.\li:tre of minor side effects that the pi!! may cause?

j

10. }?.~Y~"?.I_l...~~Y.~..'l!J.~stkms l huve not at~~-~~~<:1,:~~-?......................._.

························-·-··························-·-·-···'

Table 2. Contrz.cepl:ive l\'1ethods
r~·····----------·---~--------------~--------·················•••••••••·······------~--~-------·-~-~-~------------~----------·-····························---~----------·-·-·---------·····-----~--------------------~

i Abstinence
i Rhytlmt method of contraception (periodic abstimmc:e}
i
CaleJ!dar
Ovulation method

i
j

i

l

Symptothermal
Postovu1ation

Oral

Contraceptiv;~s

(Combined)

Transdermal Contrac~ptive Patch (Ortho Evra)
Vaginal Contraceptive Ri'lg (NuvaRi:ng)

Mir;i.pills (Progestin-only pill5; POP::)
Emergency contraceptives

Barrier contmceptives
Diaphragm
Vaginal contraceptive sponge
Cervical cap (Pr.entif Cavity~rim®)
Female condom (ReaHi:y~))
Vaginal spem1icides
Male condoms
Injectable C<mtraceptives
Depo-Provera(fp
Lv.nt~lleCJ,<)

Ir.tnmtcrir: e Devices
Progesta~a;rt@ IUD (with progesterone)
ParaGa.rd(E>(Copper T380A IUD)
Min~na@ (!l.lD with levonorgestrel),
Implants
lmplanon
Norplant (no hnger availab.le in the US)

Steri1iz.ation
.Fernak
l\,laie ( va~cctomy)
L CoiJu;; i~_!_{:.~-~-lJ!J::~_s_·---·-·-·-·--·-·-·---~-·-·-·-·-·-· ----·-·-·-·-·-·-····-··-:--active patient. The less patient-dependent a method,
Uni{ntunately, the difference m contraceptive
the cioser the typkal us~ge i.s tn the perfect usage.
effectlvenes~ between perfect use and typical use
Tims, methods such as the implant, DMPA, and TUDs
leads to n:d lEons of unin.t(~nded pregnancies each year.
hav~ typical usage that is viriually equal to perfect
Perfect use is defined as correct~ consistent, and
usage, and the in.t ravaginal ril'1g and transd~crmal patch
continued use of a method chosen by the sexuaUy
h;tve b~Ut~r rypica1 usage than OCPs,
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Table 3. Effectiven ess ol' Methuds

...M.~.!~!.~~~~..............................................=~~~:-------------·r:p~-~i~~i
..u~~----..................... ....................-t-.1.TvJ;ic-;·:
.
.-" • '·--u;~-" : ...----·------------------------------....:!
OCP
Ottho Evra

i > 99%

--------------'f";(jg~~- - -- - -------·

--N~-~a'Ri~;;...............................................................,...?.~.:2-Y.-~

, 95%
....................... __.___=Tii99o/~----....................................................1l

....................................~~---------. . .. ~-~~-~~~t1:C~~~==-~-=--=~---. . . . . . .... . .=:~

i.2 "'·

...P.M:~:~........................................................
: 99..:Lt?...---- ------------------------.....
! .v.:
J
Mir£.1?.~................
...............................1..~-~:-~!.:'c.....................................
99. 9'Y.o............................................................J
...t~~~.S!r.r:2.________................................
! 99.4%
........................... ,.. 2.9.2%
.
i
Condoms
_ .....................1-- !t~~-;--------------·-----------·--_-...................·........ ··8·1·-~-~·-·_;'__~_Y__.;_._*_-__ :~~:·...::.. :--.:-................................._~-- - - -~..!~~B!~~~~.:.
.......................................__
. .,_.___..;.........:.:.c::..:...::~----,
--- ---.. ..
.>

*post mark~tir.g P~ari index o1'0.024

T aMe 4. Method~ to DeHver Steroids

ways of contracepiive steroid release (Table 4),
p(c)chidng a number of potential advantages. (Table 5).
Atter OCPs were developed in the 1960s, the

r-c-.-- -- - - - - -- - - - · ----·----··-·----··--···--·
P{(l~

Patch
Injeetablcs
Implants
V::;gina1 Rings

empha-~ is

Hormone-releasing lUDs ---------------............- - -----'

Tabte 5. Advantages ofNewn Contraceptive Methods
t~-r~fib~-ti~~~-~~~-~~-----------------------~----~-

-------

,.,
~
;
;' .::~nsy
,,or th,e·ado.escent
to usc
! In.creased number ofoptions
! Improved compliance
Low honnone doses
. Cm1tinuous low levels ofho!mones
Reversible
:....;:;.::;..;..==:;.._-------·----------------------------··'
·_i,:

!,':.

The barrier rnethods (male condoms, d iaphragms,
cervical caps, vaginal sponges, female condoms and
vaginal spermicides) arc not tyvically recommended
as the ~ole contraceptive method for adolr~'>cents,
unless they are mature and motivated enough to use
them; ev(;n then, pregnancy raks are higher than \vith
th(~

methods identified above as the most effective
ones.
()ver th(~ past 20 years_~ a n-;.H11ber of ne_\\ter
contr;i.ccptivc methods have been approved in the

United States by the Wasbngton, DC .Federal Drug
Administration;
thes e
include
emergency
contraceptive::,; (Preven® , Plan B®), l)epo~P:·ovcra®,
the ce:vical C;3.p, Lu.nell t:@ (injectable contraceptive
wi1b
estrogen),
Mir~na®
(an
IUD
\vith
levonorgestrel), the contraceptive patch (Ortl.HJ

Evra®) cand an intravaginal rrng(NuvaRi.ng®). Over
the past I 5 years, research has developed various

has been on having plU formulations that

have reduced estn1gc:n and progestin dosages along
with the development of phasic and extended dosing
regimens as well as the above tnentii)twct newer
hormone delivery methods.
This chapter reviews some of these important
methods of cont raception. Figure 1 lists fr equency of
contraceptive use by sexually active adolescents in the
lln.i ted States.

Oral contraceptives (OCPs; COCs)
One of the main contraceptives for several
decades has been the combined oral :.;ontrac:eptive
(COCs), containing synthetic estrogen (llSua.lly
ethinyl estradiol THE], occaslonaHy mestranol) and
synthetic progesterone (Table 6) (l-7).

The mechanisms ofactic}n for the cCJrnblncd birth
control pill (OCPs or <;OCs) to prevent pregnancy

include inhibition of ovt\la.tior:, cervical mucus
thickening, endometrial atrophy, and tubal transport
changes. When discussing OCP~ with adolescent'>~ lt
is helpful to note the many benc.fits and uses of these
pills, as listed in Table 7. OCPs are usual1y available
as 28 oay packs which contajn 21 days of ac:ti vc pills
containing consistent steroid dosages (mono -pha~ic)
and placebo ri11s for the last 7 days to allow the
adolescent fo continue with oi1e pill a day.
Variations are being developed, suc.h as having
only two days of placebo fot each 28 day cycle and
ex tended cycles.
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W~~§~r (~;-·,·:~! (Xyitf.t!{X-:~ >~!V(; ~_PWJ
)<~~-~t t>:·~(~H·:r~<:~~i

N~--~

rr: ~ti1~F;f

~ ~--:-~~;-r: ~:)~:-::::":_;_ c~ nd c-::;~:·;·.kH-:"'~J

/\H

n !"~:~~~r--:n~~ (k:4 f-~rn~::·:{~:-~

f)~::r:,n:-t{;\t~ :.~f )t) n ~d ~.ex~.:~~~
;;···: h~n:.-:Jl.:rtl.& ~-~-~ -~ : :·i~:~

:-J ~nc:ntf's

Figure l, Contraceptive use among never-married female adoJesce;1ts 15-19 years of age who had sexual intercourse ht the
past 3 months, by specif1ed method used at last int10rcourse and race and Hispanic origin: 1;nitcd Statt;s, 2002.

Multiphasic piils have also been developed which
contain StGrojd dosages that vaxy through the month
(bi- or tri-phasic). There 15 no evidence that
multiphas[c pills provide any benefit ever :-:;:wno~
phasic formulations and are often more expensive.
There is also no evidence that one OCP brand is better
Jban another:, only that an individnal adolescent may
prefer or tolerate one brand over another. Gcnctal!y, a
pill with bet'.veen 20 meg and 35 meg of EE is.
selected. While effic:acy appears m be the ~arne, pilh;
containing 20 meg or less of EE have been shown to
have a greater rate of irregu1ar bleeding than higher
dose piils.
Some kmaJes benefit from extending their
menstrual cycle to rcduc~ the number of yearly
menstrual periods. This method can used. in those
lJ[Piihg problems worsened by their menstrual periods,
such as those with epi1epsy, headaches, menorrhagia,

premenstrual te11sion syndrome, mm dcfkiency
anetnia, endometriosis, coagulation disorders, those
rece!ving anticoagulation, athletes wishing to avoid a
cycle during an important sports event, and vthers. 91
day packs an: cw::n.mtly cpmmen:ially available
{Seasonique@, Seasonale®, LoSeasonique@),

1\iorgestrel
i.Vorethindrone
l'-!'oreihindrone acetate

Ethynodiol aatwe
Gestodcne

Levmwrgest.rel

ll•orgesmnate
De.~ogestrel

Drr'Jspirenot<e
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Tah!e 7. Misst:d Orni CQntraccptivc l"Uh;

of PHI : Number of nilk-~n~sse·d·----------------------------------------------·---.......................~..........................J._______ .
...........................................................................<·
30-35mcg
! 1-2 piils missed:
3 or more pii!s missed*:
i
i Ta.l(e last missed pill immediatdy and
Take last missed pill imrnediate!y and c~intimw ;
' ·on~i·1·•a norma! pi" ~ak:no· scheudul ··
nort!tal pill -taking schcudldc. Discard other
l

---f~~: Do~art
--~---------·-··-M

I~actL~; ~l;tl;od n;:~~l~H~c·d~l.

..

~1!~~~~1;i~~thod need~~d for 7 days.

t;.

I

!----------+!
--------·---·-...................____....rI T;;;.--;;;~~~:;,-pills
Consider EC . missed* :
20mcg or less
1 oi!t mi.tsed:

-i!
Take _l-ast, ~>is.se_d pil.l in:nuediat~ly and c~ntinue !

· ..

T~k~ J_ast misse_d pill irt~ediately and
contmue nonnal p1l1-takmg scheudt1le.
Back-up method net needed.

i

,1 normal pll;-mkmg scbeuduh: . D;scarcl on1er

I missed pHis.
! Hac:k--up method needed for 7 days.
I Cons1der EC.

i
i

_____________ _!

*Ifmissed''j)iii'S'"Cc;-~-;:- during 3rd ~~~~k~-!inf~h active pills, disctmi p!accbos, and start new pack.
T able- fi. Use of Ond Contracepti-v~s
to )Han age Val"iou~ Disorders

A.cne vulgaris

~---------------- ---- -- -- !

I

i

Coagulc>pathi c:~

(Aritkoagulatlon Therapy)
Decreased risk of ectopic: pregn~mcy, ovarian
and endometrial cancer

i
i
·;
i
i
i

i

Dysmenorrhea
:Epilepsy

i 11eadaches

smenonhea due to .:ating disorders,

,.
,.
,.
,.

>
>
:->·
>
>·
>·
<·
>·
>·
>·
>·
:- :- >·
>·
>·
>·
>·
>·
>·
>·
<·
>·
>·
>·
>·

'
'
'
'
'
'
'
'
'
'

Sunday Start.
This may cause connJston, difficu.hy witb.
\Veekend refills, and delay in initiation, especiaLly in
won'len with irregular menses, Table 8 provides

instruction on mari.agement of missed pills. The
sexually active adoh:sce~1t should be instru(.;ted that

! Endometriosis

:·
:·
:
:·,.
,.
,.
,.
,.=· ·

also be started on the first day of the next menses and
no back-up method iii ne,~ded. Lastly, they may be
started on the Sunday after the next menses, although
h•~ck- up contraception is needed for 7 days with a

exen:ist:, stress
Iron Def1ciency Anemia
Menorrhagia
Polycystic Ovary Syndrome (PCOS)
Prematr:.re ovarian faih;re/Tumer syndrome
Pr<~menstrual Syndrome (FM:S)!Ptcmcn.stmal Tr:ension
Syndrome (PTS}
! Rheumatoid
.Arthritis
.
..···- ····-·······-···············"""•"""•"""•""'•"""···--·------ -........................................
~--.--.--

OCPs may be initiated a<:cordin g to th1'ee differe11t

OC.Ps (COCs) do not preve.nt sexually trans mitted

diseases, ar.d thus, condoms, are also recommended.

Contraindications to OCPs/COCs
Counseling

sexual!y

active

youth about OCPs
involves discussing conditi.ons that may present
increased risks for tl-10 adolescent. The World Health
Organlntion (Wl:!.O) has published guidelines for

me(.!ical digibiiity to hdp in this f.ndeavor (Table 9).

Sunday

'Females in WHO Cat(:;gor:y I have no restr:iGtions

Start. .A urine pregnancy te:st may be performed if

to using OCPs, while those in \VHO Category 2 have

some increased medical risk. Hcwcvcr, OCPs and

,' .

patient ha:. 1lad Ut1protected sex since last menses, <md
should be repcatc<t if r1ext men.&es is missed Qt there
are other c.onccrns for pregnancy. Emer gency

,' .
'

contraception may be considered if unprotected sex
has occurred in the last 5 days.

pregnancy may outweigh the medical co11cerns.

For the Quick Start method, the patient should
take the ilrst pill immediately and back~up

increased risk that they are not placed on OCPs uD.less

'
'
'
,' .

,.

sched ules: Quic~ Start, First Day Stan and

contraccptkm should be used for 7 days (24 ). Quick
Start may improve comp1iance, decrease confusion,
and provide near irnrnediatc contraception. OCPs can

!
tr::·.

~

other combined hormonal contraceptives should still
be considered fnr those in Category 2 as the. I'isk

'-"~f

Females 1n WHO Category 3 have such an
there is no O"thet available, effective, contraceptive
agent. FinaHy, those in 'NHO Category 4 are not
placed on the OCP because the medical risks are too

great.
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c~tegory

- -- ----------------------------------------------------------------------------------------------~---------------------------------

One (Nu Restrictiom>)

Antibiotics
Benign breast disea:-;;~
Benign ovarian tumors
Cervical ectropion
Dysmenorrhea,
Endometnosis
Epilepsy
Family history of breast cancer
Gestational trophob!a~tic di~easu (benign or malignant)
Headaches (mild)
Histmy of ectopic pn~g11ancy or abortion. (posi abortion after first or secDnd
trimester),
History of gest&tional d~abetes
Increased STD risk
Iron deficiency anemia
lrreguiar menstrual bleeding
Obesity
Ovarian or endometrial cancer

Past pelvic surgery
Pelvic inflammatory disease
PGstpartum at or over 21 d<Jys
Thyroid disorders (as hypo/hyperthymidism, simple goiter)
Varico&e veins
Various infectiGns :malaria, tuberculosis, others)

Sexually transmitted diseases
Viral hepatitis carrier
Category Twu (Caution)
:Cervic..a} crtncer
Diabetes mellitL!s (ur.comp1icated)
Headaches (severe and ifthey start after beginning OCPs)
Hypertension at 140-159/J 00-1 09 mrn Eg
M~ior smgery without prolonged immobilization
Migraine headaches without focal neurologic involvement.
Patiems who hav~ a hard time taking the OCP correctly:
d.wg or alcohol abuse
mental retardation
persistent history as poor OCP takers
severe psychiatric dsorden;
Sickle cdl disease or sickle C disease
Undiagno~;~,:,d breast mass
Category Th:ree {D~uaHy no OCP given)
Gatlbladdcr disease
Lactating (6 weeks to 6 months),
tess tha,n 21 days postpartum
Mcdic:::.tions t.hat interf~re with OCP efilcacy
Undiagnosed abnormal vaginnliuterine bleedbg.

Categ·t1:ry f.o1c~r (OCP contraimlicaterl}
Bn.:a~>t cancer
Ccrebrov;~scuiar accident (adlve or history)
Comp!icated__~E::!-Ef.~~£al heart disea~r:t'-"~-~tQ.P~.!!,t_~~-~:~ExJlYOcrtension , atrial

>::::;::::'"

:·:::.:;::: :

.· ·.: .~

:.:: ::::~·:..

L.
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acute bacteria1 en Joc_G_l_'ri-. i-ti-:-.)-------------------------------------------------------------------------------------------)

Coronary {or ische~ic) heart disease (active or bi;t~)r~)-,
Deep vein thrombosis or pulmonary c~1bolism (activ~ ofhi."tmy\
Diabetes mellitus ( complicabl wii~1 retinopathy, neuropathy, n-e~luop:~thy)
Headaches (including migraine headaches) with f()cai neurologic symp\oms
Hypertension (severe: ( J60-'-/ l J 0+ mm Hg or with vase-dar eomp lications}
Lactation under 6 ;vceks
Liver disease (inducting Ever cancer. benign heeatic adcrwma. active viTal
hepatitis, severe cirrhosis)
...
·
,
Pregnancy, complicated

i

i

i
i
i

I!
!
l

---------------~~~~-')J'I£J.~.'?.~-~:~~8.!E:~l'?.~~:-~~--~~-~r-~:.l_1jtiE_s__~.~~J/?E.f'.l_-~?.~~~!'.g~-~:.i_f!:1mcJbiti;ation

*lhcd with pcnr;issiDn ±rom Grey dan us DE: Contraception. ln~ Course Manli.aCfo·"'.r.::....:A..:.d:.:.:o..:.Je::...s_c_e_n
__t_H_l_Cf-d~tt-1.-E-·-d-s:_D_•-E-.-G-Jr_e_y....JdamJs,
DR Patel, H Pratt, S Bhave. Ch. 20:309-324; 2002.
. .
.

Cardiovascular risks and OCP!S
If the adolescent has had a venous thrombcisi~ in the
past, OCPs arc contraindicated (25-27). Venous
thronibosis (VT) risks are greater in the adolescent
and young adult female than risks for arterial
thre:mhosis, Morbid obesiLy is a weU-kno>vn risk
factor for VT, though the an:wunt of increased risk in
tbc otherwise healthy adofesccnt is not lmown. Most
adolescents \Vho develop a VT do not have
idcntiftable dsk fq,ctors. S~rcedng questions fm~
adolescent~ seeking OCPS in regards to VT are Ested
in Table H),

Smoking shou1d be discouraged in the adolescent

but is not a reason by Hself to avoid OCP::;. Blood
presstw: can increase in those on OCPs and should be
monitored. E there is. a personal or family history for
increased lipids, the OCP is permitted if the ]o<,v
density lip<,.)protein range is under 160 mg/dl or the
trjglycer1des under 250. Other guidelines ;nay be used
by the clinician if these guidelines are not accepted in

one's region.
TaMe lL llisk Factors for Tbomhosis
r--r~:e;~~iincy---------------------------------------------------------------------------------------1

Tijh]e 10. Qut.~jinn.§ abont persun~llfamily bhtory
~1f thmmboemhoHsm

Factor V Leiden mutation

i

Prothrombin mutatior1 G2C2l0.-\.
Hyperhomocyste1."'1em.ia from mutations in

I

MTHFR ~rene-

I Deflcicncks of Proteins: C, S, or antithmrnbit! m
l
'· Have you

or a dose family me1nber
(including uncles/aunts) had blood dots in legs
or lungs?
Have you or a cio~>e family member been
hospitalized for blood clots in legs/ltmgs?
3. Have you m a close family member taken
binod thinners?
i!
! 4. Under what circu:nstanccs did the clot fom1? i
'
:
L__j~.:.,_i£:_ during air trave!)
_____, ____________________]
Table 11 lists risk factors for thrombosis. Death
from cardiovascular disease {arterial and venous) can
occur among 20--24 year old. femaks at 2-6 per
million per year.
Thus, death from the OCP is a small, but known
risk, though the risk of death from pregnancy is much
greater. The OC? should be stopp~d if the adoh.!sccnt
has a condition requiring prolonged bed rest, as with

major surgery.

!':,,!·

l
i

i

I

Synthetic oestmg.e·n use
Tobacco usc
Other nwdica! risk fadors: immobilization, surgery
(c~pecially orthop~cdic ami pelvic). cancer, obesity,
severe i1hess, other thr"Ombouhilias

·----------~------------·-··-··-··-··-··-················..t··--------------~--~--~-----~--~---------

There arc a number of so-called "minor" adverse
effccb thilt are wd1--knovm with OCF lJS<.:, su.ch as
headaches, mood cnanges, nausea, and. bn:r,st
tendemess. These effects are usually toietated, and do
disappear with cessatlnn ofthe pill.

Though often linked to OCPs, there is no dear
evidence that weight g~tin is the directly caused hy
OCP/COC use. Uterine breakthrough bleeding can be
seen with OCPs and is a common cause for stopping
the OCPs. Bn~akthrougb bleeding usually resolves

··:

.,
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\vith continued use ofthe same OCP. Occasionally a
change to anothe~ brand is necessary. If the break
through bleeding is signit1cant, the patient shots!d be
evaluated fot other cm1set>.
Adcikscents
with
\Veil--controlled
diabetes
mcHitus usually do weU with low dose OCPs; OCPs
arc not continued if complications arise, such as
hypertension,
retinopathy,
nephropathy ,
or
r1europathy. Some clinicians recommend that OCPs
be avoided in those with migraine hc~ad<:.ches having
auras and in thosl) \Vitb. worsening headaches on the

OCP.
Some anticonvttlsanLs lead to reduced OCP
efficacy. These include barbiturates, phenytoin;
carbaxnazcpiEh', feibamate, t()piramate, and vigabatrirL
A number of other medication:; can also interfere with
OCP efficacy, such a.s rifarnpin, gri,.;cofulvin,
ketoconazole, Hraconazole, and others. Antacids and
OC?s should be separated by at least 3 hours. Those
>vith c.cti vc: Liver disease should avoid OCPs.

wearing a patGh over 7 days, patch detachment, and
not placing a patch afLcr being off for 7 days. If the
patch detaches, [t should be reattached lmmediatdy. If
the patch cannot be reattached wtth its own adh~3i.ve,
a new patch should he placed and the patient should
place the next patch on schedule. Tfthe patch is off tor
over 24 hours or the patient is more than 2 days late in
changing it, a hack-up contraceptive method should
be used for 7 days. Some concem has been raised that
pregnancy risks rn<'-Y he increased in fcmaks over 90
kg. COC efficacy is reduc~,;d in cbese females but is
better than noted with use of barrier methods alor;e,
This reduced. efficacy is due to increased basal
rnetabolic
rf;l.tCS,
augmen-ted
adipose tf~suc
sequestration, a.nd increased hepatic metabolism of
enzymes f<ll..lnd in obesit-y.

NuvaRing vaginal ring
Nuva.Ring is a flex[ ole, transparent, soft vaginal ring

I'ra.nsderma1 hormonal contraception
Ihe use of the patch to provide contraception has
become a popular method for many adolescents and is
based on decades-long research in using tra.n~dermal
rnechanis:ri1s to deliver medication. Patients should be
advised that the same adverst: effects as OCPs apply,
with the possible addition of increased tm~ast
syn1ptoms, and 1ocal dermatitis at tbc patch slte. The
c:ontra1x~ptive patch is about the size of a matchbook
and placed on th~ skin in various .sites: upper outer
ann, buttocks, upper torso, and abdomen; it is not
placed on the breasts or skin tbat is irritated or cut,
The patch produces a daily release of 20 meg EE and
150 meg of norclgestromin, a hormone that i~ the
active metabolite of nnrgeslimate. The patch is
typically start~d on the first menstrual day, replaced
weekly for three weeks, and then no patch is placed.
on week 4 alkr.ving menses to occur. A Quick Sta;-t,
as discussed above, may also be used for initiution.
A dil:Iere:nt site is chosen with each patch application.
Pregnancy rates ate simUat to the OCPs, 0.7 ro
1.24 per 100 \l.'oman--ycars with the patch versus 2.18
for OC:Ps*. This rate is net affected by exposure to
watet baths or saunas, strenuous exercise, or wa:~m,
humid climates. increased r~sks for pregnancy include

made cf an ethylene vinyl acetate copolyrn~r with two
steroid reservoir cores providing a daily release of 15
mg EE ami 120 meg of etonogcst(el (desogestteJ
metabolite). It is placed in the vagin<:! by the
adolescent for three weeks and ihen removed for one
week. Quick Start is possible. If the ring is expelled, it
;s sirnpty cleaned and placed back in the vagina; if the
ring is removed fbr nver 3 hours, l1 back--up method of
contraception is needed until the ring is back !n the
vagina for 7 days.
lt is an excellent meth:J<l of contraception for
those who are comfortable with thdr bodies.
Adolescents are ;jfkn reticent to use the ring due t<j
the method of insc;tior, and removal. Insertion (~a:r: be
simplil1cd by placing the NuvaRing in an empty
· tampon applicator and using the applicator to insert
the ring, The user ne~ds tn be: counseled that the ring
does not prevent STDs.

Advantages

of the

rhg

indnde

exi;ellent

contraceptive efficacy, easily placed as well as
removed, confidential method, continuous hormone
release, and rapid return of ovulation after cessat!on
crf the methi.Hi, Potential adverse e!Tects include
vaginitis, vaginal qiscornfurt foreign body sensation,
as \.Vel! as the common side effects of all COCs as

mentioned above.
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Progcstin~only pills (POP~} provide wntracepdon by
cervical mucus thickening and endometrial atrophy;
ovu1ation 1s rim reliably inhibited, leading to
pregna.tK)i rates of 1-3 or rnore per 100,000.
Prog{~.stin::; used in POPs include 0.35 rng of
norethindrone (Mictonot@; Nor-Q,D®) and (1.075 mg
of norgc;;.trd (Ovrette(R)),
POPs are suggested by soln<~ dlnicians for
sexualty active females with c. contraindication w
estrogen (such as hype11ension or coronary heart
disease). They are also used in females Vl•ho are
breasth:eding. Typical adverse effects of POPs
include amenorrhea and irregular uterine bleeding.
PO?& ~hould not be used by females with eCtopic
pregnancy history or taking certain medk:atlons, such
as antkotnrulsants, rifanipin, and griseofi.1lvin. POPs
are not typicaUy recormnended for adolcsc:cnts due to
th~: above increased pregnancy risk and the need for
an active piH (no placebos) to be taken at the same
time daily making compliance diftkatlL for teens,

~

Emergency contraceptives

. ··=
.·..:

Table 12 lists some of the emergency contraceptives
(ECs) that have been available (28). The Yuzpe
regimen Uf>es a combination of Ef! (1 00 meg) and a
progestin and results in significant. nausea due to the
high dose of estmgen {use of antiemetic is
recommended}, while Plan H contains kvonorgesLrel
enly and thus produces less nausea and has been
shown to be somewhat mor~ effective than the Yuzpe
regimen. The n;pccted pregnancy rate from one
unprotected coital episode is about 8%; this is reduced
to less than 1% with some FCs if used within 24
hours of unprotected sex, EC is most effective if used
within the first 72 hours after unprotected sex t)r

contraccpti£m failure, but may he taken up to 5 days
after coitus. If the patient is pregnar1t while taking
ECs, the fetus is nm harmed. ECs are over-thecowiter in many parts of the world. They shm1ld not
be used as regular contraception, Reasons to nse ECs
include having sex \Vithout protection, slippage or
breaking of a. condom, missing 2 or more oral
contraceptive pills in a row, barrier contraceptive
dislodgement (such as a di~phra.gm or \x~rvical cap),
intrauterine device (IUD) dislodgement, or being owr
14 weeks from the la~'t Depo~ProveraCBJ injection.

al;etate
(Depo~Provera@;
Medroxy-prcgcstcrone
DMP/\,) is a commonly used injectable contraceptive
that inhibits ovulation. th[ns the endometrium, and
thickens the cervi<;al mucus. l.L is most commonly
used m the intramuscular formulation, but a
subcntat1ecus version has been developed which m:ay
show promise for self administtation in the future .
It is a reliable contraeeptive if taken on. a regular
basis at a dose ofl50 mg CV(oty 12 weeks. A very low
pregnancy tate js noted at O.J%.. It does not contain
estrogen and thus, can be used for those ;.vith
contraimlicatioas to using estrogen. Bone loss is noted
ili, adolescents on this contraceptive ·· an average of
3.1-5% after 2 y~ars of use. However, several studies
have shown significant bone mineral density ;·ecovery
after cessation of DMPA, thot;gh it is tinciear yet
whether DMPA decreases peak bone density \vhen
used during adolescents. Therefore, DMPA should be
used with caurion in youth at risk for low bone
density, such as those with chronic renal discr,sc,
anorexia nervnsa, and those with limited mobility
(29). Use of Depo-Provera often leads to irregular
mcnstrualperiods and then, amenorrhea.

··--·--·-·-·-·---·-·-·----·-·-· - - : - - - - - - - - - - - - - - - - - , - - ;s

<~>
l,.

._.

~

OvTalt£: : 2 tablets hy mouth immediately followed by 2 tablets in 12 hours

LoiOvrs.l®, NorckUG@ or Levlen(ID : 4 tabs and 4 more in l2 hours
TrlPhasilCK) or Tri-Lev1en® {yellow tnbs only): 4 tabs, and 4 mote in 12 h<)urs

Ovrette®: 20 tab<> :rnd 20 nwre ln 12 houn
Prevcn® Emergency Contraceotive Kit
l-·--~----··--·------------·--~--···------·--------~---~---------~----··-··--·-~ Plan B®: levo;orgestreL 0.751~~1>-~----------------···""'
filllowed hv- - ·--0.75
rno in l2 hours
··· ····-·····w .................. ____ .:_________
~
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Ac.oe
Amenorrhea
.Behavicrai. changes (depression, anxiety, ilTitabi.lity)
Breast tenderness
Decreased bone densitvJ
Dizziness

,
ii

!

Fatigue

.

Glucose inwlerance
Hair loss
Irregular menstmal bleeding
Nausea
.... ~Y.~~ght gain
-~------······························'"····----------------·------·-----------·-----------

!
1
!

:
'i
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·-.rab1e 13 provides a partial list of adverse effects.
Bcnef21s of this contmccptivc include. re1iable
contracqition, reduced dysmenorrhea, .less seizure
a,{:tivity in some females with epilepsy, and lower
premenstrual tension syndrorne.
Other injectable contraceptives that are available
Hre LunelleJJ) (United St:;:tes); Cydo-Provera, and

Cyc.lofem (5 m.g e,st:radiol cypionate anct 2.5 tng
medroxy -progesterone acetate fMPA /F:2C]); these
corobinatio.n injcctablcs (containing estrogen and
proges.teronc) ~re given intramuscularly every mont..lt
(every 28-30 days) aml have v~ry high contrac.eptive
efficacy . Si.nce it cnntains estrogen, dysfimcti onal
uterine bleeding and amenon·hea arc n ot as common
as noted with Depo-Frovera. Another injectable
product is J\.ksi:gyna® (with 50 mg of norethindrone
and 5 mg of estradiol valerate).
'l'ht: ctonogestrel-releasing implant ((l.vailablc as
Implanon® in the US £>ince 2006) is a subdermal
implant consisting of one 40mm long, 2mill diameter
.rod. This rod Js wade up of a core cqntaini.ng 68 mg
of ctonoges't!~ei within a rod of ethylen¢ vinyl acetate
copolymer covered in a mcrnhcrane nf the same

matcri<J.l .
Thi::1 implant is inse;ted sLibdennally, t);pica1ly in
the region of the bicipital groove, using 1hc sterile
preloaded inserter. I.mplanon provides 3 years of
contraception by releasing a steady dose of progestin
ca;;sing inhibition of ovulation and increasing cervical
mucus viscosity. As a progestin-only mctl1od of
contrac.cption, the implant does not have the side
effects or contraindications associated with estrogen.
containing methods . Unlike Medroxy-progesterone
acetate, the implant does not c~mse decreased levels of
estrogen and thus does not decrease bone density .

The benefits include high efficacy, lo ng-acting,
non-estrogen contain1ng, -.ost effective, rcquin':s little
e!Tort of th: part of the patient, rapid rewm to
fertility, <:md the benefits of other progestin only

me\hods.
Adverse affects include irregtllar bleeding,
headaches, acne, weight gain, pos$ibk rnond
disturbance, and increased blood pressure. If irregular
bleeding occurs, the patient shou!.d he evaluated for
other causes.
f.f no other cause is found and the bleeding is
sig nificant or disruptive for the patient, NSAlDS,
combined oral contraceptives (varying regimens), or
et.hin_yi estradiol have been shown to be effective to
tl'eai brea.k throl<gh bleeding due lc the hnplant and
pos.si,.~ly other progestin-only methods as welL
The eflect of Implanon may be decreased ih those
with liver disease and by medications that induce
CYPJA, :mch as many antiepiteptics, r ifampin, and

..··.· .·
..··.·.·
:: ·:

St Jr)hn 's wart. Ukc DMPA., many women eventually
experience amenorrhea with the impiant. Barriers to
use ~ncludc cost and the need for insertion and

removal.
The need f<:>r removal by a trained profe.ssional
may also be -seen as a be.net1t in the adokscent
population as this gives the prac1:!1wner an
opportunity to couilSei the patie11t on family planning,
safer sex practices, additional contraception options,
and conduct appropriate screening prior to the
adolescent discontinuing t.:.1is method, which may
decrease unintended pregmncy. Overall, implantable
contraception is an excellent option for teens.

··::::;::
••••••••••
.: :.. ·:
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Intrauterine device {llJ D)
.A nu:m.ber of IUDs are available in the world: the
three lypes avllilahlc in tJl(~ United States are
Progestasert IUD®, the PamGatd® (Copper T380A)
and the Mirena@ HID. ·rable 14 lists the
contraceptive mechanisms of IUDs. Pmgest(l:>ert
IUD@ is replaced annually and has an: expulsion rate
of 2.?%, \Vhile ParaGard@ is replaced every 8 to IO
years and has an expulsion rate of 5%. 1n Lhe United
States, concern has been raised abottt a possible link
betM.'ecn its nsc and peJvic inflammatory disease in
female:;; due to often criticized research d.Htlng to the
1980s. Though controversial, it has 1im ited the use of
IlJDs in adolescents in the U.S; it is used by 12%, of
contraceptlve.using women throughout the world.
Data on the currently avai!ablc IlJDs show no
increase [n risk of PlD unless the patient has an
infection -,vith Chlatnydia o:- gonorrhea at th~ lime of
p1acemenL Therefore, patients should be screened for
STis prior w fUD placement

--·----~------·------,-----·-·------·-·-

1.
2.

3.
4.
5.
6.

.............................

Prevents fertilization
interferes \Vithovum dcvelopme11t
Interferes wtth sperm movement an4 ability to
penetrate ovum
T:nh!bits ;;penn survival
Helps prevent egg release
Thti:kcm; cervical. !YHlCU.S.

Mirena lUD (.Lcvonorgcstrel-containing IUD;
LNG--IUD) is a second .. generation of steroid-releasing
TUD. It releases 20 meg of levonorgcstrei per 24
hours over the f!rst 5 years of use, decreasing to 10
meg per day after 5 years. 1t is. a popular ru D used by
over 2 million women in the world. lt has a failure
rate of 0.2% in the first year and 0.7% at 5 years. It
exerts a local effect on the endom.et:rium as well as the
cervical mucus; ~.wul!ltion may continue and
endometrial thin.r:ing can lead to aJneDorrhe~t. Table
15 lists potential adverse ei'F::cts of Minma HJD, the
most common of which is irregular bleeding. It has
been used. to reduced menstrual bleeding in. females
with dysfunctional uterine bleeding, because it can
reduced
menstrual
blood
loss
hy
90'Yo.
Contraindications to Jvf1rcna IUD use include

413

distorted uterine cavity, bistory of St~b acute bacterial
endocarditis, prosthetic heart V<J.1ves, and active pelvic
inf1atnmatory disease .
Tab!e 15. Mtrcna.lUD Side Effects
....................- - - - - - - - - - - - - - - - .

Common
Initial increased menstrnal bleeding.
Abdominal pain
lJncomn;on
Acne/other skin nrobJems
Back pain
_,
Breast tenderness
Headache
Nausea

.l\-1ood changes
Rare
Hyperscnsiti vi ty reaction
IUD become~; embedded in myometrium
Perforation of uterus or cerVix

ParaGard® (Copper T380A) is a copper T lUD
which prevents pH~gnancy by the interference of
sperm motility by the copper ions. PamGard® is
highly effective INith a first year failure rate of OJ~%
with typical usage and a high rate of continuation
among adolescents. The primary b{mefit to
ParaGard® is that it is non-hormonal a:"ld can
therefore be used as reliable contraception in those
-,vith contraindications to hormone use, history of side
effects with hormonal contraception or those patknts
\Vishing to avoid hormone usage for other reasons.
Adverse effects are primarily increased dysmenorrhea
and menstr:..:al bleeding, abdominal pain:, ex.pu.!sinn
and rarely perforation. Contraindications are similar
to t.:.1ose for Mirena. in general, lUDs are a safe,
effective, long-term method of birth corrtrol that can
be used in nulliparous adolescents. \Vhik not
recommended for teens at high risk for STls, IUDs
have not been found to increa~c risk of PID, nor have
they been found to affect future fertility.

Barrier :methods
Diaphragm and vaginalspermicides
Table 16 lists banier contraceptiv(~S. Tbes;:. methods
are only recommended for highly motivated sexually
c.ctivc individuals. Clinicians can lca.m to fit
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diaphragms, help determine the proper size and teac;h
the youth successful use of thio: methoi.L The
diaphragm is used >vvith vaginal cream or foam and is

often used with the (:ondom. Vaghal contraceptives
or spertnicides include foams, jellies, crearns,
suppositories,
and
a
tCntmceptive
film.
Contraindications to diaphragm use are listed in Table
17 and advantages of vaginal contraceptives are listed
in Table l 8. Side effects inc!ude vagind odor and in
mre cases, allergic reactions. Females w·ho have
diabetes mellitus and use a diaphragm have increased
risks for urinary tract infections. 1n rare cases, tuxic
shock syndrome may occur and the diaphragm is
conrraindicilt~d in a female having a history of toxic
shock syndrome.
Table 16. Vaginal B!lrder Cm&tracepti.ves
....-----"'"''"'"''""'"'""'"'"'"'""'"'""'"

size of a diaphmgm and. fits around the cervix vla
suction. FouT cervical sizes are ava~labk and about
one-fou.rth of females cannot be fitted with a cervical
cap. The clinician should obtain cervical cyw)ogy
betore and at the time of cervical cap fitting because
cervical dysplasia has been reported in cap users;
additional cervical cytology i1> also recommended
three n:wnths after the fitting, Contraindk:atinns to cap
u;;~~ include cervical laceratitm, cervical scarring, and
a history oftoxk shock syndrome.

Vaginal contraceptive sponge

Table 17. Contnlindications h> Ust; ofth~ Di~puragm
..................................

Retroversion (severe; backward. tilting of uterus)
Short anterior vaginal waH
Vesicovaginal (or rectovaginaJ) fir.tulas

Female condom

i

Toxic Sho_~~.-~:Y.~!-~~:~~~!e_-_ _ _ _ _ _ _ ..................!

Allows the mnr to shar(~ contraceptive i
responsibility when used 1-vith a condom
i
Can reduce: dyspareunia if present (vc.gimil j
lubricat~t)

i

Cost is minin1at
!
Prescription is not needed
Provides effective contraception, espeddly if
used in conjunction with COi1dom or diaphragm

Side effe.cts are f~w1
Useful for young women witb only occasioha1
--·····--··---··--···········----------

The sponge is made of polyurethane with 1<. concave
:.<hapc; it is a disposable method available without
prescription, inserted in the vagina up to 2 days before
sex and lefi in place 6 to 24 homs after cohus.
Adverse efTects inchide vulvar rash, vaginal odor,
pruritus, candidiasis, and increased risk for nrinary
tn~ct infection as weLl a:; toxic shock syndrome. Its
contraceptive eff'.cacy is similar to other barrier

contracepti\ics.

AllcrJ;<,Y to rubber or spcrmicides
A.nteversion (severe; f<.nw~t.rd tilting of uterus)
Complete uterine prolapse
Perineal tears

coitus

The PrenH® cavity-rim cervil~al cap is a smaH, latex
cap ('Nith spennicid~ p1aced insi.dc) that is hc.lf the

------·-··············,

!
Diaphragm
!
!
Cervical cap (Prentiht'))
l
Vaginal contraceptive sponge
!
!
Vaginal spennicicks
!
!
!
Femal<:·condoxn OlealltyCRJ)
't
Male
condom
..................:=::...:.=:.__ _ _ _ _,................................._ ____;

~-~-~

C"'!ervical cap

The female condom is a polyurethane bag or sht~ath
that does not require a pn:.~scription. H is placed in the
vagina prior to coitus; it is not used with a mate
condom. Some STD protection is provided by the
fen1ak condom and its ov{irall contracept[ve efficacy
is similar to that of other harriet con\:raceptives·---·
acceptable, but not as good as oral contraceptives.

lviale condom
!Vlale condoms ;1re recommended to reduce the risk
for STDs a;s well as pregnancy. Their contraceptive
effil~acy is similar to (?ther b<1rrier methods. They must
be Llst:d com~ctl:y vvith each act of coitus or their
efficacy becomes considerably reduced.
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Latex condoms are associated wi:tll inc:n~ased
breakage rates when exposed to high temperatures
and/or ultraviolet ligr:t; they are also \veakened by
exposure to oil-based lubricants. Latex. allergy is
noted in 7% of the general population and. the
polyurethane condom can then be used. ln genera\
!Ttale condom usage should be encoumged. in the
adolescent population primarily for sexually
transmitted infection (STI) prevention. Ho\vcver,
barrier methods are typkal1.y not recommended as the
sole method of birth comro1 in adolescents.

f·
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~:
~:
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r·

~:-~··

..

:~:·

Conclusion
Contraception is an important concep.t for sexlca..Uy
active youth who wish to prevent mnvanted,
un.pianned pregnancy. This papet has fi~Vlewed
effer;tive methods of contraption that ax~ available.
Clinicians caring tor adok;Scents should ask abcmt th.e
sexual behavior of the~e youth and provide advice on
contra<:eption, beginning with abstinence.
Sexual responsibility involves prevention of
unwanted prcgtw.ncy, prematu.re childbearing, and
ST1s. A surmnary of contraceptive options for
sex;;aily active adolescent females having chronic
illness is provided in Table 19.

Table 19. Chronic Disorders autl Contraception (Greyd:.nms, 2010; ZOHI; WHO, 2004; 2008; CDC, MMWR, 2010.)

!,', ,', ,', ,'

,_:·:",n()ti[p_-P·.h.i_o,js,"

1

. DMI';\ or the Mirena fUD/1US

See increased risks for thombosis tn
the~e

patknts and thus, avoid COC.s.

AntibDdy

Risk of thrombosis is

cspcc! ally incre.ascd if
oth{;r t;sk factvrs tor
thmmbosis are present

Avoid COCs in these p<11i::nts with
n:wdcratc or high titers of
anhphospholipirl antibodies (i.e., at 0r
over 40 GPL or MPL Lmil:s).
>·~·:------"'""!"-:~-····----·--·--·-·-------·--·-.--·······-·--...............~·-······----·-----·-·-·----·--·--·--·--·'--······· ..··········......
i Cancer
Potentially All Methods; see- vm·ious COCs a.rc contraindicated i!l 1hose with
COCs m3y reduce risb
:
cautions. ~·or example:
breast cancer. Progestin and estrogen
for.ova:rian and
'
1
Avoid DlV!PA if taking
receptors arc noted in ovz.rian c;.;ncer
endometrial carcinoma.
!
!
cbcmoth,~rapy dc;<; to increased risks
tissue: thus, COCs ;;.rc not prescribed to
Pr~:E,"'I<mcy wurs~::n~ breast
for mf(;ction trom roec;iropt~nia or an
patient> with ovarian cancer. A..void ih(;
c~nccr~ cndorn.etr.!ai
~ancer, ovarian cancer.
inJcCtion-i:Jduced h~::mawma due to
mini-pin with a posith.-e hi~tmy for
th.romhoc)topcnia (t CP).
ecwplc pregnancy or if taking meds.
malignant gestational
\Vlth drug interactions (i.e., certain
trophob!asli1; disease,
Cbemcthcrapy-ind;.Jccd bone kss
may be m~reased by DMPA. Avoid
a...'l.ticonvulsant:;. g~·ise0fulvin, rifampin).
malignan1 Ever tt~rnors
TUDs ior those wi1h ne1~tropenia m
(lwp<s.toma) and
TCP. C:ru;:ion >Vith ~:qntmcep1iye
l;epatocetlular Ever
(aPf)
Syndrome

l

-----~--------~--~----------------------~----:

hnplants for those \vilh TCP and

Disease
(CHD)

DMPA and min~·pi1l l).re
rt:etwmwndcd for thos{! with CHD
stable. Mirsna EJD/HJS h nsua!ly

u·

OK. Observe for potential adverse
reaction~

f

I

!
!
!
·--·-·-·--·--·-·-·-·-_j

carcinoma (CDC, 2010).

~---c~--:---:-----i~1rr,..,..~":g::-u..,..la_;_·n_,J7e_n_~i:-;-'·u_a'-lc:b::-l_e_c.:..d_in'-"g.:;:.··----+-:=:----=:-:-:--:--:--~---:--:--:---::--+-:----::---.
Cun.gf.nilal
.!-kart

:

:
:

during nJD pla;;ermmt,

such as syncope., bradyt,a:rdi<~. lmd
seilures ..Avoid JUD if patient is on
~! rrtit.nagJ.J laHoa due to incre.as~~1 ris~.
for bleeding with IUD placement.

Th(lSe on COCs have insJeast:C! tisk fo~
thmmbophlcbitis, vascular tf::rnmhn~es

Fe:nalcs with v~.lvda.r
!!<::art disease <md other

(attcrial or \'enous), and pulmonary
embolism. Void COCs (im.~luding patch)

GHD may be at
cndoc-a.rdit].s risk clnt[ng

vvi\h a positive history for these

IUD placement and 0ne

c0nditinns. See the >ext.
Avoid COCs if there ls ir.creg.sed r:sk
for thrombo·Emho1ism or
cndccardnis~-depcnding on the type of

.rnonth after the p laccnwnt
l'regna.'l.ey 1s a,;sociatcd
with incrcas<:d adV{;fSC

CI·ID. COC:; (im:1uding Llu; patch} arc
avoid\:d in \.hose with CHD with cmdiac

.her>.Jt d.isease, complicated

health effects in ischemi.c

outputcurdiac disorders, il.·'ld r;nmnary

va lvnh;- heart disease,
pedpartum cardiomyopathy, stroke (CDC,

heart di,;ease. Avoid.COCs (includLng

20 lO).

shunts! congestive

~1earf diseas~:

!ow

patch) in. those vdth CI-IJ) 3.:ad

··--·--·--·--·--·-·-·-·-········---·--··---·--·--·--··---·--··-'-··P.:!;~:~.?.~:~:Y..!'-lE.er\c~si_o_n_,_______.......____________...,~
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T!lble 19. (Cmttinued)
Coi1ccrns

Disordct

i

~--------·------+--. . .~

All methods art acteptahk if

Diabetes

the metabQHc status is stable:
COCs, DMT'A. mini-pill, lUDs,

mini-pills.

:
:
~

j

COC5 5h0uM be uvuided h1 any
adolescent female: \ViLh diabcti;;
compbcations (pedpherul V<lS<:ular

COCs do not worsen the

disca:oc, ncph:ropatily, and retinopathy),
va:-!culr:.r s~quc]a.c (i _.e., -venrlus
thwmbosiS), or hypencnsion. DJ'vlPA i~
S<lkev~.n with the presence ofdiabct(::;
compl;catioos. IUDs IrElY in.dm;e dt.ronic
or resistant Canditfq afbi.cans v.a.gi.niitis in
some.

gcstodcne, and dt:sogestrel)

tnetaho;ic status. Nc\v>':r OC
(norgesti,'"Datc,

progc~tin~

may cause lcs;; carbohydmLe
metabolism dkcts than the
older progcslins.
Pregnancy is as~udat•:ii with
increased adverse h~·i:llth
effects in lnsu1irHiep~;ndu:nl
diabetes meifit!ls with

l

i--·i::pii~ps):·-----·-tnMi>;\;-'rUi).(Mi;;;~·-;,~a····--------tc:;-,;iiO-i~-v.iti1-c55t:~·~;~;-~;-~;~r-e-~~~;·t;;··-··---- -~~~~~~~i~1~~ifi~¥.~~:,l~,olo;.
.copper); Barrier wntraception

:,i' ,,,',,,

interfcn~ncc with some an.ti::pileptic
dmgs with i.."lercascd pregnancy risks:
Catbamazepim: (Tegn•:ol)

inen:.:JS('.d ri:>k tor pn:gnmu;y
and pokntial teratogenicity of

anticpikpuc mcdkations.
Pregnar;;;y lS assc1ciated with
, Phenytoin (Ditantin}
increased adverse hc~.lth
Primidonc (Mysolir.e)
. effects in epilepsy (CDC,
i
Topiramate (mild inducer)(Tapamax)
!
20 i 0),
...................................._..............................._...._....................t··----·---·,··:··::----:~----.-···:·--·---· . .. . .
~--·--·--r .. ,............,.......... ---::,----........;
HyperAll methods il.rt rccommcnned
AvoHl CO~-~ ;f :ow de.tiSli.y hpopwtems i Res;;;arch nok~ t..'lat estrogen
1ipidemia
for stable hyperlipidemia.. Use
(LDL) level is over 160 mg!dl,
can tower high density
Jow-·d\)SC COCs.
triglycerid-;;s arc over 250 mg/dl, nr in
j lipoprotein levels, r;tisc LDL
Phenobarhitai

i

l

sit.nat1ons with the existence ofm~c!tipk
r-i$k f;lCtOfS' for C0(0tl(H) artery d_igem)e.
(CAD): diabetes meUitus, hypertension,
obesity, smoking and positive faa1i!y
history for premature CAD.
1

trig !ycerid~ levels.

........~--;---::------:--c:--:----+--:----:--'-----'..O-'---'--'--:--c-'--'--~.,......,,..---1--:-:--:-:-:c-----:--:---,.,..

r-.-:-c--~-·-·-

Al] mctbds are used ;JjJle-:
;;(~ndition is stable.

}·lypef\ension

--+-.,-:---·-----...................................

Inflamma-

AH methods are usllillly
acceptable, A. void DMPA on a
prolonged basis in those on
corticostemids chle to bone lnss

tory
Bowel

Diq::ase
(IBD)

t;:cK~exbation.

~--:-:--·-----··--

lntcllcctual

! levels,. and increase

Avoid ~strogen..cQatnining m~lhods for
CO(:s re~u!l in a small
unstable hypertension (such;~ bbod
incr<:a~e in h]o,,d pn:s~u..:.·<.:~·
prct>~ures over 160/ W{l mm !!.g),
highc:rincr.::ase in ~mecdot:::.l
?·regnancy is associ;!tt:d vl'ith increased
si(uations.
adverse hea.!tll ef1~n~ in um:cmrolled
hypcrknsion (CDC, 2010).
........................~~-~----·----·----+---------................--:----:--:---........;
COCs may reduce bowel symptoms in
i DMPA may reduce break.-·
3.ctive en litis; COCs dficncy may b0
j through ·ble~diflg and
: serondm:y "n..:mia; may be
lowered d;Je tn inc-reased br0ak-fr..mugh
:
bkedir.g and reduced OC c~bsorp!iD!L Use ! hest tor combi!1a(ion of IBD
tt;e patd1 if ga~trc;inte!;!.ir!~l absorption
I and coag;;lation disorders.
way bt: ap!oblcrn. Mirena !l_JD/!US
nppe<1rs to l:J<:, dketivc 11.nd safe.

............~-;----;--,------+-Sec schizophrenia

Disability

Liver
Disease

-~--..1..l)Mc::P-c-1-c-\-a-t-,(..,.i...,!""t"";=D-s-,-,r-e--s-a..,.fe-,,-, t'h-t--1\,--v-o-c-i-:--dCOl's in t.hose with-;z~-v~~t'i_v_e_r--+-,-!n-(-,:1:-d:-<:-.t-;c--~::-o"""r...h..e-.pa-ti~·;;·ic·--·--·--··
1:-.

! activ<! liver disease. Barr(e;·

I contmce.ption i:; also fin;;
! (ex<xpl for-the increased

d[~ase (indudir;g hep2,t[tis anrJ

cirrhosis).

COCs are 0[( when the Ever

function te~ts retllm to normal. linknown
\be effect of obt:sll)'·induccd NASH
(non-alcohn!ic steatoht:paiitis) em CCC

adenoma is 3.4/!00,000 pHi
users. Pregnancy is

us::>ol~iatcd

w·itii incrca~ed adverse heslth
df<c:cts ;n severe (deC".ompensated) cinho:;i~ (CDC, 2010) .

! pregn<Jncy risks inhcrcm ir; th;s
! method).
..-~·-·----·----·--·---------~-------------··---·--··---------·--- ..:?!!}E~~I:...............------------1----------------i

i

i

.......................... ::

-'-------------'------------~----'----------
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.• __.......Tr.-~~- :.-n·;~;:~.·l·~.::·····-·n·······-·· ········· · ·

··· ········- ~ -~~ ·-· ····· ··-!. ·R~··::;:_·o-·rr.·
.-~r~
. ·.··n~(·~d "".t .".l"··t ,",ol~ .-

f-.....,,......-.,.---4-:: - -~-~----"-':----:.-_~.:: ......:~::....

,r

Mlgr:;.ine
H eadache:;

ndditton to barrier
contraceptive~.

1

i Depo-meciroxy-

(DMPA), the mini-pili

I (progc~t::ror:c-0ni.y pU!),

l tmd the Mi:rcna rm) rn
ii

.

!

i

i

~ ~

i

i! progc:;;rror,e act: tate
1

--~---··n-.· -·· ··· -··-··-··-··-·· -·--··· · ...-·--··...· - - -

.....................L~-~~~!.~!~:~::~.~.?.~_:_1:1~nts_.__
· ·---..·-·-...]
i Females witb cnmpl!c;1ted migmim:
i l.J~e COCs with caui!on l.n those !
hcad~chcs {Le, witl; neu:oicgical
vlith mlgrainer. ~wd stup if auras .i
i
i symptom s) have heightened risk tar
develop andiG;- ihc headatbes
! q:n:b<<J.l i~K:hemia and ccrcbmva,;sculat:
j he~:om~~ worse.
accidents (CVA5) ifpiaced on comb ined l
! o n;! wntra.cept!ves
o f estrogen
__

!.·

!

I

bec.aus~~

1

1.

d tects
I
["ob'e;i;;;...........TL~~;~;~o•gcstrd mu arJc! 'TcocS.-;~:;-·g;~~;ct·;~~.TI~iien;_e_n_t_c..,·t-lP_i_c_~-,-~"".<.'-.r-.-i:~c""'o~c:~---<~-r::-::fi:-c-·!1-,(.-.y-. .,..is_·_rL-·d·;;;<;~r·;r;·(~J;;;-;;;·!
! rnini-pills .may be .tbe hest i obese y .mth needing contraception a;:
tcmal~s but is bette~· thar, use of
option Jig lh(;; morbidly
i w ell as pc·lv(vst.i(' ovarv svn·h·r>mr·
1 barder methods ~!kate., The
'i o'--~e a"<'.!.~
:
.~ ..... _ "":""·.'-·- ......,
. I "r
1:,
'""' '-' ·• .- s~.:-..._n:~-.
,._..~ CO'"l~S
_ !lr
.
!llt,.JU5m, an•d.; acne
vu;gans.
ii: re'ducc·d et""~!It;-(lcy :s
(.ne <0
i
I
i
..
I
t
! DMP/\ may induce weight g<lin r:nd this
i increased hasal mcta:ilclic rates,
1 in.tra.vagi n a~ ring 1rre
1
i rcc.om;r:cnd~d u nless
l should be closc.ly monitored.
! a~1gmentcd adipose t issue
sequestration, and
an~c
(as thro mbo!
.
.
: hepatic metabolism o f e:nzymcs.
~
C[n bolisrn) other~) .
t
:
~..·f;~~lmona.ryjAn mcthi;ct:~-;;:~~-u-~;;;~p:t~;;;~-~.. (OCs arc safe and eft'ect ive
............. i-:c·aii..tise..;\iEi-;;t·h;d~·:fi~·u~o-.-s-e-~-,·-lt-:-h-.-;

i

.i,

~ t~slrog<;u•;;ontraindicatlons

i,:.

~ Dise~c

!

.

.. ....

-

.

;,.

in~;rcascd

l

!i .

't

! in thu~t: with CP. l:>n.mclllai mucus l~ not i ~thma. IIpulmon ary tubcrcubs is

I in paiients with cy;tic

fibro sis (CF} with np other
cantraindl.ca}lons for

:

.

contraceptives.

! thkken~d to a major ::;xtent (as with
I

1 cervicatmucu.s) to interfere with
contraception. I'ulmonacy embolisn r (PE)
! is a rare cvr.nt .... :?,void COCs if other high

I

!

is p resent, rifilmpia can dect-..:asc

! COC efficacy.

ri ~k fact~..'TS {OI PE arc present in cr
rernates.
Re;-u!"············"· ""i'f'tiic"tcnai"di~~~as~----·---lc-:cc:-:::
o(:s liTe s~fC fo7'ESRi5'iTre~1~1T5tai~"'is'-;--;c:-:o=c:-:s-l_
n_a_
y"""i_i n_p_!~.()-V_C_l_
n_c_n_o~-.r-:h-·a-g7ia-i
:'
1,
1

(indt1ding en d sta~c renal
rlisea<;e-..ESRfl) is stable ·-OK to w;e. COCs, DM PA,
M i~~cna ItJDf[(;$., llnd
barrier con traception.

Disease

noi .irnp uim l (~table) "Yith no
hypertension, c~rdio·va'icu!ar di~>eas~:- and
thromhoembo(is m. Estrngcp i~
contmindicatcd in those w ith hSRD w llh
signilkant hypertension or if bed~ridd~r ;.
Avoid DMPA )Cbo ile ·klss is of concern.

Avo id the 1U D with

i

Barriers

. o id arthritis
{RA)

I

rb k of

cndOnlttriti-s anri v~~ors·e~tin,g: ane:::~i!.~·............) ...................... ------·--·--··-··-·--.--------11
Potentl<tl concern. wllh IUD s du'-" to
j Avoid COCs is L'le.-e is i:wn~;;scd

cocs, De;;-:};;:o~era,

Rhew:nut-

iJJ.cr~a~e d

rtl some wilh E SI{D.

poten1iai infection.
Females with severe IV', ·may have
diffiL'ulty inserting a vaginal ring,

dia_p hT~gm, cervit:itl cap, or ether barrie:

contraceptives.

· risk fo r va>culitis, (}Qwrosd~ro·
i
li sis, or ischemia See pos~.ihle drug
i.·Hentc{i(l!lS between COCs anti

RA tlnJgs, s ltch as warl~rin,
cortiCostCr!).lds cyClospor.ine~ and

·-.....-... ......-......-....................................._·-:---:---:---+-s-:-' . ,.H. .,le-:-:-a_n_t
r,.
i,..c_o_,._,'~-~!:0.~:~:::.....................)
I

COC:s. IkJio ..J'mvera,

Sickk Ccli

Baui•~rs

i Dison.k:rs

I (S:CD)

~ickling cr!se~. Pregnancy is as~ociated

!

·t

'

t
t

~

............................. .f. ........ ~·· · ·· ~·-~·-~·

! COCs nwy be the bc~t

f Sl.E
i (Systemi c
Lupus

i

i

!

l
i Erythematvsus)

Pregn ancy in,;rca$eS risk for both mother
and fet us. COCs do Ml increase risk dm:
10 sid::.ling; Depo-Provcra may reduce

I
i

•~hoicc.

with increased actvem: health e!J:bGL'> in
.s!·ckle celt disease (CDC!' 20 10)
Avoid COCs in the
vasculitis, nephr!l:i$, o r APLS. Avvid the
prcg<~Kterone dmspirenone ifrerJal failure

preser:ce·;·[".........._

llot\:d since

hypcrkalemi;;. c;m devel!.lp.
Pregnancy is associated with ir;creased.

Siddi'ng is a different process
t..1.ml thrombosis :md thus, COCs
do not increasC'l'isk Ji.)r

thon:-.bosis.

i
i
i

!'
i
i
i
i

l
l
,l

:

:
D.~~ -~JA n~ ay W'Orsen bo.rte t:oss

already pre sent ill SLf: pati ent !~ .
Avoid the fUD due to the lowered
irrHUUl'C ,.;.aius c-f sr E patient<
.
.
• ~- .
. • ~.
...
l

:. .______!. . .----~. -........-.............-,-:..~;_·~--~~·~. :,;:. s~ ·_h_e_al_t_h_e_:f _.c_·c_su__in_s_L_E_-'_(_c_D_(_:_,--...J..--- - ------..-.....--..···~·_j
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1'ab1e 19. (ConJ.inued)

~-JI:,f;"sce!l..

aneons

HIV. DMPA 'Nork;;
v,-di. Altcrnat1ve: HJD.

HJV: I'otcntid dwg !nteracticm between
COC::; and c.:rtain ~.nti-I-IIV drugs; ~orne
cause dccrr:a.se in estrogen ((lopinaviri
ritanawr and nevir-apine) and some owsc
nn increase in estrogen (ala.:anavinmd

l!IV: use condoms as -;_ve!l to protect
partner from BIV trilllsmission.
Pregnilllcy is assoc]ated witb
incn:used adverse health effecls !n
H.!V/AlDs {CDC, 2.0HJ).

'--------·-- ------------------·-·~-----'---"-f!}_i;_v_ir_::!El:............................~-------'---~--------------------------------------··~----'
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